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Abstract
Objective
To characterize the genetic background of molecularly undefined childhood-onset ataxias in
Finland.
Methods
This study examined a cohort of patients from 50 families with onset of an ataxia syndrome before
the age of 5 years collected from a single tertiary center, drawing on the advantages offered by next
generation sequencing. A genome-wide genotyping array (Illumina Infinium Global Screening
Array MD-24 v.2.0) was used to search for copy number variation undetectable by exome
sequencing.
Results
Exome sequencing led to a molecular diagnosis for 20 probands (40%). In the 23 patients
examined with a genome-wide genotyping array, 2 additional diagnoses were made. A consid-
erable proportion of probands with amolecular diagnosis had de novo pathogenic variants (45%).
In addition, the study identified a de novo variant in a gene not previously linked to ataxia:
MED23. Patients in the cohort had medically actionable findings.
Conclusions
There is a high heterogeneity of causative mutations in this cohort despite the defined age at
onset, phenotypical overlap between patients, the founder effect, and genetic isolation in the
Finnish population. The findings reflect the heterogeneous genetic background of ataxia seen
worldwide and the substantial contribution of de novo variants underlying childhood ataxia.
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The most common etiology of ataxia in the pediatric pop-
ulation is genetic, with the prevalence of genetic childhood
ataxia in Europe estimated at 14.6 per 100,000 population.1
Determining the etiology of childhood-onset ataxia has im-
portant clinical relevance, including ending the stressful and
costly diagnostic odyssey, guiding genetic counseling, and fa-
cilitating precise follow-up and treatment.
The most common causes of hereditary ataxia vary regionally in
populations of different genetic backgrounds.1 Owing to the
founder effect and genetic isolation, Finland has a unique disease
heritage.2 Accordingly, the most common ataxias seen elsewhere
in the world, such as Friedreich ataxia, are rare in Finland.
As next generation sequencing (NGS) technologies have
evolved, there have been many reports of exome sequencing in
single families or single cases with childhood-onset cerebellar
ataxia.Many previously reported ataxia cohorts analyze patients
with adult or varied age-of-onset3 or are defined by having
structural cerebellar abnormalities4–6 instead of the symptom
of ataxia. There are a few smaller studies that analyze cohorts of
pediatric patients with the symptom of ataxia.7,8
This study applied exome sequencing and a genome-wide
genotyping array to examine a cohort of patients with
childhood-onset ataxia collected from a single tertiary center,
allowing better characterization of the genetic background of
molecularly undefined childhood-onset ataxias in Finland. An
age limit of 5 years at onset was applied to demarcate a clinical
entity within the heterogeneous group of hereditary ataxias
and is based on the Human Phenotype Ontology (HPO)9
defining childhood-onset as onset before the fifth birthday.
Methods
Patients
We reviewed all pediatric patients who were diagnosed with
ataxia as the primary symptom of their disease in a single ter-
tiary center (Helsinki University Hospital Child Neurology)
during years 1999–2018. An overview of the study is shown in
figure 1. The exclusion criteria are provided in appendix e-1
(links.lww.com/NXG/A269).
Thirty-three children from 25 families seen in the Helsinki
University Hospital Child Neurology clinic between 1999 and
2018 for the onset of ataxia younger than 5 years had a mo-
lecular diagnosis made outside of this study. The etiology in-
cluded pathogenic variants in the genes ATXN7 (2 families),
CACNA1A (4 families), C12orf65 (2 families), DNAJC19,
FOLR1 (2 families), NARP, NKX2-1, PDHA1, SCN2A,
SCN8A, SLC17A5 (3 families), SUCLA2, and TWNK (4
families). In addition, a 6.4 Mb deletion in chromosome 10
(10q26.2q26.3) was found to underlie ataxia in 1 patient.
We invited families with children who received a clinical di-
agnosis of an ataxia syndrome of an unknown etiology and with
onset of symptoms before the age of 5 years to participate in the
study. We recruited 50 families while 2 families declined par-
ticipation. In families with multiple affected children, we se-
lected the first child referred to our clinic as the proband. From
October 2014 through February 2019, we performed exome
sequencing on samples obtained from 50 probands.
Routine genetic screening was not required before entering the
study, although single gene or gene-panel testing of known
ataxia genes had been performed for some patients before the
study. In this regard, if the treating physician suspected a spe-
cific genetic etiology, for example, infantile-onset spinocer-
ebellar ataxia, a disease belonging to the Finnish disease
heritage, the gene in question may have been tested before
recruitment into this study. Table 1 describes the clinical
characteristics and demographics of the cohort. For all patients
in the cohort, diagnostic investigations for ataxia had begun
during early childhood. The results of a clinical microarray
comparative genomic hybridization (CGH) test performed
before the study were available for 46% (23/50) of all pro-
bands. Twelve patients (24%) were either prescreened or
screened during the study for pathologically expanded tri-
nucleotide repeats (appendix e-1, links.lww.com/NXG/A269).
Standard protocol approvals, registrations,
and patient consents
The study was approved by the Helsinki University Hospital
ethics review board. All patients and/or their legal guardians gave
informed consent in accordancewith theDeclaration ofHelsinki.
Phenotyping
A child neurologist with expertise in childhood-onset ataxia
examined all patients, whereas all available clinical, laboratory,
and imaging data were reviewed by several clinicians un-
dertaking the study. Primary phenotypes weremapped toHPO
terms9 and included in the in-house semiautomated variant
prioritization pipeline.
Sequencing and bioinformatics analysis
We performed exome sequencing on genomic DNA for 50
probands, 2 affected parents, and an affected sibling in 2 families.
GLOSSARY
ACMG = American College of Medical Genetics and Genomics; CADD = Combined Annotation Dependent Depletion;
CGH = comparative genomic hybridization; CNV = copy number variant; ExAC = Exome Aggregation Consortium;
GSAMD = Global Screening Array Multi-disease; HPO = Human Phenotype Ontology; NGS = next generation sequencing;
SNP = single nucleotide polymorphism.
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The variant calling pipeline of the Finnish Institute of Molec-
ular Medicine was used for the reference genome alignment
and variant calling.10 We prioritized recessive-type non-
synonymous variants with a minor allele frequency of less than
0.1% on the Exome Aggregation Consortium (ExAC)11 server.
For potential de novo or dominantly inherited variants, het-
erozygous variants that were not found at all on the ExAC
server were prioritized for consideration. We further prioritized
variants by their predicted deleterious effect using amino acid
conservation and, in the case of potential de novo variants, by
gene constraint to mutation according to the framework pre-
viously described.11 The prediction tools SIFT12 and Poly-
phen13 as well as Combined Annotation Dependent Depletion
(CADD) C-score14 were used in variant evaluation. Variants
with a CADDC-score14 of less than 10 were excluded. Variants
were also compared with our in-house database containing 520
exomes.
We classified novel sequence variants using the guidelines
provided by the American College of Medical Genetics and
Genomics (ACMG).15
Sanger sequencing was used to validate the variants identified
by exome sequencing and for segregation analysis. In the case
of P12, samples from the child’s biological parents were
unavailable, and as confirmation, western blot was used to
confirm the deleterious effect of the variant identified.
Technical information on exome sequencing, a list of the
primers used in Sanger sequencing and details of experimental
validation of variants identified for P3 and P12, is provided in
appendix e-1 (links.lww.com/NXG/A269).
Global screening array analysis
We screened for copy number variation and uniparental disomy
after exome analysis was negative in 23 probands, for whom there
was available DNA, using the 759993 single nucleotide poly-
morphism (SNP) markers of Illumina Infinium Global Screening
Array MD-24 v.2.0 (GSAMD; Illumina, San Diego, CA). Log R
ratio and B allele frequency values were generated with
GenomeStudio 2.0 software (Illumina), and copy number varia-
tion regionswere detectedwithPennCNVsoftware using standard
quality control checks.16 Standard quality control of genome-wide
genotyping data was performed with PLINK 1.9 software.17
Data availability
The data that support the findings of this study are available
on request. The data are not publicly available because of the
information that could compromise the privacy of research
participants.
Figure 1 Study flowchart
Number of families with children with
ataxia syndrome seen in the Helsinki
University Hospital Child Neurology
Clinic in 1999–2018. Patients were re-
ferred from the Helsinki-Uusimaa re-
gion (catchment area population;1.7
million, ;30% of the Finnish pop-
ulation). The Helsinki-Uusimaa region
is highlighted on the map. GSAMD =
Global Screening Array Multi-disease.
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Results
Diagnostic yield of exome sequencing
We obtained amolecular diagnosis for 20 probands (40%) using
exome sequencing. We identified 26 diagnostic variants in 16
genes, 13 of which were novel and include a variant in the gene
GPAA1 that was published from this cohort.18 A recessive form
of inheritance was found in 9 probands, with 3 of the diagnosed
probands having homozygous variants and 6 having compound
heterozygous variants. We identified dominant variants in 11
probands, including de novo variants in 8 probands, 2 familial
autosomal dominant variants, and a suspicion of parental so-
matic mosaicism in 1 parent of 1 proband. In all familial cases,
there were no pedigrees involving 3 or more generations.
After multidisciplinary evaluation, a novel variant in COQ8A
and STUB1was considered diagnostic for the probands’ ataxia
although they remained as variants of uncertain significance as
per strict application of the ACMG guidelines.
The diagnostic variants we found are listed in table 2. We
annotated variants to the Ensembl19 canonical transcript for
each gene. Allele frequencies are reported as found in the
Genome Aggregation Database.20
Diagnostic yield of genome-wide
genotyping array
We uncovered 2 copy number variants (CNVs) that we con-
sidered pathogenic using the GSAMDgenome-wide genotyping
array. For P21, we identified a heterozygous 570 kb deletion in
the 10q26.3 region (chr10:131538728-132108832), encom-
passing the genes EBF3, GLRX, LINC00959, and part of
MGMT. The same deletion had already been identified in the
patient’s clinical molecular karyotype when analyzed in 2015 but
was, at that time, considered to be of uncertain significance. The
parents of the patient were screened for the mutation, and it was
found to be de novo. The GSAMD finding prompted re-
evaluation of the deletion. Since 2017, haploinsufficiency of
EBF3 has been reported to cause hypotonia, ataxia, and delayed
development syndrome (MIM #617330).
For P22, we identified a heterozygous 1.2 kb deletion in
SLC2A1 (chr1:43392250-43393465), encompassing most of
Table 1 Demographic and clinical background of the
cohort
Sex n (%); n = 50
Male 25 (50.0)
Female 25 (50.0)
Ethnicity n (%); n = 50
Finnish 40 (80.0)
Other Caucasian 3 (6.0)
Middle East 2 (4.0)
Southern Asia 2 (4.0)
Multiple populations 2 (4.0)
Unknown 1 (2.0)
Pedigree n (%); n = 50
Nonconsanguineous
One affected child 39 (78.0)
Two or more affected children 5 (10.0)
Consanguineous
One affected child 2 (4.0)
Two or more affected children —
Affected parent
One affected child 2 (4.0)
Two or more affected children 2 (4.0)
Age at onset of first symptoms n (%); n = 50
Congenital (at birth) 3 (6.0)
Neonatal (birth–28 d) 5 (10.0)
Infantile (28 d–1 y) 26 (52.0)
Childhood (1–5 y) 16 (32.0)
Imaging abnormality n (%); n = 50
Presence of abnormality on brain MRI 33 (66.0)
Cerebellar atrophy 22 (44.0)
Cerebellar atrophy and additional findingsa 3 (6.0)
Cerebellar hypoplasia or dysplasia 4 (8.0)
Cerebellar hypoplasia 1 (2.0)
Cerebellar dysplasia 1 (2.0)
Hypoplasia/aplasia of the vermis
and molar tooth sign
2 (4.0)
Other abnormalityb 4 (8.0)
Abnormality of peripheral nerve conduction n (%); n = 17
Presence of abnormality on ENMG 5 (29.4)
Sensory axonal neuropathy 2 (11.8)
Sensorimotor axonal neuropathy 1 (5.9)
Table 1 Demographic and clinical background of the
cohort (continued)
Demyelinating peripheral neuropathy 2 (11.8)
Intellectual developmental disability n (%); n = 50
Presence of intellectual developmental disability 22 (44.0)
a Findings additional to cerebellar atrophy: brainstem atrophy (2); basal
ganglia abnormality (1).
b Other abnormality: hypoplasia of the cerebellum, pons, brainstem and
corpus callosum (1); pontocerebellar hypoplasia (1); small volume of the
thalami (1); mild cerebral cortical atrophy (1).
Results of an ENMG study were available for 17 patients.
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Table 2 Diagnostic variants underlying the patients’ ataxia
Chr Pos. Start Gene CDS position
Functional
change
gnomAD
AF Finnish
gnomAD
AF All
CADD
C-score Inheritance
Reference/ClinVar ID if reported
previously (annotation in report) ACMG classification
P1 1 43394882 SLC2A1 c.971C>A p.(Ser324Ter) 0 0 44 De novo Novel variant Pathogenic
P2 1 227169808 COQ8A c.811C>T p.(Arg271Cys) 0.0007748 0.0001061 33 AR Reported29 Established variant
P2 1 227174171 COQ8A c.1677C>G p.(His559Gln) 0.002802 0.0004296 26.4 AR ClinVar ID 423260 VUS
P3 2 191116992 HIBCH c.559C>T p.(Leu187Phe) 0 0.00003185 29 AR Novel variant Likely pathogenica
P3 2 191159358 HIBCH c.220-2A>T r.spl 0 0.00001769 24.3 AR Novel variant Pathogenic
P4 2 219525942 BCS1L c.232A>G p.(Ser78Gly) 0.004062 0.0004737 23 AR Reported30 Established variant
P4 2 219526485 BCS1L c.464G>A p.(Arg155Gln) 0.000008838 0.000003994 25.8 AR Novel variant Likely pathogenic
P5 3 4709128 ITPR1 c.1736C>T p.(Thr579Ile) 0 0 29.5 AD Reported31
(Thr594Ile)
Established variant
P6 3 4856866 ITPR1 c.7786_7788delAAG p.(Lys2596del) 0 0 22.8 De novo Reported32 Established variant
P7 8 145138112 GPAA1 c.160_161delinsAA p.(Ala54Asn) 0 0 29.9 AR Reported from this
cohort18
Established variant
P7 8 145139371 GPAA1 c.869T>C p.(Leu290Pro) 0.00004704 0.000004020 26.1 AR Reported from this
cohort18
Established variant
P8 10 131640542 EBF3 c.1183C>T p.(Arg395Ter) 0 0 42 ADb ClinVar ID 620273 Pathogenic
P9 10 131676043 EBF3 c.625C>T p.(Arg209Trp) 0 0 35 De novo Reported33 Established variant
P10 10 131676045 EBF3 c.622dupA p.(Met208AsnfsTer56) 0 0 35 AD Novel variant Pathogenic
P11 11 6636680 TPP1 c.1259C>A p.(Ser420Ter) 0 0 40 AR Novel variant Likely pathogenic
P12 12 111057639 TCTN1 c.221-2A>G r.spl 0 0 24.9 AR reported34 (IVS1–2A>G) Established variant
P12 12 111085142 TCTN1 c.1635+1G>A r.spl 0.000008845 0.000008022 24.8 AR Novel variant Pathogenica
P13 13 77575055 CLN5 c.1175_1176delAT p.(Tyr392Ter) 0.0008137 0.00009384 35 AR Reported35 Established variant
P14 14 36987093 NKX2-1 c.596C>A p.(Ser199Ter) 0 0 39 De novo Reported36 (C2519A) Established variant
P15 16 732184 STUB1 c.689_692delACCT p.(Tyr230CysfsTer9) 0.000008841 0.000007985 35 AR Novel variant Likely pathogenic
P15 16 732442 STUB1 c.865G>A p.(Val289Ile) 0 0.000007998 23 AR Novel variant VUS
P16 17 57775212 PTRH2 c.127_128insA p.(Ser43LysfsTer11) 0 0.000003979 24.3 AR Novel variant Likely pathogenic
P17 19 13346507 CACNA1A c.4988G>A p.(Arg1663Gln) 0 0 25.4 De novo Reported37
(Arg1664Gln)
Established variant
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exon 9 and all of exon 10. Mutations in SLC2A1 are known to
cause GLUT1 deficiency syndrome 1 (MIM #606777) and
GLUT1 deficiency syndrome 2 (MIM #612126). Multiexon
deletions in SLC2A1 are known to cause disease.21 The
GSAMD finding was confirmed with multiplex ligation-
dependent probe amplification in a clinical laboratory and
confirmed to be de novo.
Patient phenotypes and effect on
clinical management
The findings of the study affected the clinical management of
multiple patients. Table e-1 (links.lww.com/NXG/A268)
describes the patient phenotypes and possible effects on clinical
treatment and management.
Variants of uncertain significance in
ataxia genes
Four probands had a variant of uncertain significance in a gene
previously implicated in ataxia, listed in table 3.
Gene of uncertain significance
We found a heterozygous de novo missense variant for P27 in
a gene not previously linked to ataxia,MED23 (figure 2A). The
patient has hypotonia, tremor, and ataxia that developed at the
age of 1.5 years. A detailed phenotypic description for P27 is in
appendix e-1 (links.lww.com/NXG/A269). MED23 encodes
a transcription factor in which recessive mutations are known to
cause autosomal recessive nonsyndromic mental retardation-18
(MIM #614249).22 De novo status was confirmed by DNA
fingerprinting of the patient and parents using 7 microsatellite
markers. MED23 has a high constraint for missense mutations
(missense Z: 4.53556). The variant, chr6g.131919485A>G,
c.2549T>C, p.(Leu850Pro) has a high CADD C-score (28.6)
and causes the change of a conserved amino acid (figure 2B).
Discussion
Exome sequencing is a robust diagnostic method for
childhood-onset ataxias manifesting before the age of 5. We
found disease-causing mutations in many different genes in this
cohort despite the defined age at onset, phenotypical overlap
between patients, the founder effect, and genetic isolation in
the Finnish population. This is surprising because Finland has
a unique disease heritage; however, our findings reflect the
heterogeneous genetic background of ataxia seen worldwide
and the substantial contribution of de novo variants underlying
childhood ataxia.
The patients who were investigated with exome sequencing
formed a “hard-to-diagnose” cohort, which did not include
patients from the same clinic whose genetic diagnosis had
previously been made by single gene or panel testing. In this
study, the combination of exome sequencing and GSAMD
provided a diagnosis for 44%of the investigated families. This is
slightly higher than in ataxia cohorts comprising patients with
varying ages of disease onset, where an estimated diagnostic
rate for exome sequencing is 36%.3 Our diagnostic yield was atTa
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the same level as other smaller exome sequencing studies of
symptom-based pediatric ataxia (46%–80%).7,8,23
The percentage of genetically diagnosed patients that were found
to have a de novo variant underlying their disease in previous
studies varied. In the first such published study,7 in a cohort of 28
families (6 consanguineous), 9% had a pathogenic de novo var-
iant. Our study revealed a remarkably higher de novo rate of 45%
in patients with previously molecularly undiagnosed childhood-
onset ataxia. Other reports include a 25% de novo rate in a study
that investigated congenital ataxia in consanguineous families8
and another study23 that found a 42% de novo rate in a pediatric
movement disorder cohort including patients with ataxia.
One of the limitations in our study was that in most cases only
the proband, and not parents, was sequenced. Trio exome
analysis is associated with a higher diagnostic yield compared
with single exome analysis in rare Mendelian disorders,24 and
trio analysis is especially useful in an early onset, mainly spo-
radic ataxia cohort.3 However, a large number of de novo
mutations were still identified by prioritizing deleterious het-
erozygous variants using CADD C-scores and gene constraint
scores.11,14 Nevertheless, the high burden of de novo variants in
this cohort adds to the recommendation of a triosequencing
approach. Furthermore, our exome sequencing analysis may
have underestimated the number of CNVs and may have
overlooked uniparental disomy because their analysis is not
straightforward from exome sequencing data. Software that
infer copy number variation from exome sequencing data, such
as ExomeDepth,25 can have suboptimal specificity and sensi-
tivity, especially in the case of small CNVs spanning one exon.26
In children with developmental delay, a first-tier diagnostic test
revealing CNVs has been chromosomal microarray, either with
array-based CGH or SNP array.27 Not all copy number varia-
tion is revealed even with the combination of microarray CGH
and exome sequencing because CNVs at the intragene level will
usually be too small to be identified using the microarrays in
clinical use. High-resolution microarray or genome sequencing
can still better identify CNVs, especially the long indels and
small CNVs that are otherwise not found. We found GSAMD
to be a cost-effective method to screen for copy number vari-
ation and uniparental disomy and to confirm maternity and
paternity in suspected de novo cases in a research setting. In the
patients examined with GSAMD, 4 had previous findings
reported in clinical molecular karyotypes. These previously
identified variations had been inherited from an unaffected
parent or had otherwise been interpreted to be of uncertain
significance. TheGSAMDdetected all 4 of these CNVs, adding
to our confidence in the method.
We did not find any pathologic repeat expansions, such as those
underlying Friedreich ataxia or many of the dominant spino-
cerebellar ataxias, which are poorly detected using NGS tech-
nologies.Many of the common spinocerebellar ataxias caused by
trinucleotide repeats are rare in Finland, with the exception of
spinocerebellar ataxia type 7,28 and are unlikely to be represented
in an early-childhood-onset cohort. However, repeat expansionsTa
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in novel ataxia disease genes are possibly yet to be discovered,
and identification of such mutations is likely to be enabled by
application of long-read genome sequencing technologies.
NGS techniques have become ubiquitous diagnostic methods in
centers studying neurodevelopmental and neurodegenerative
disorders. Developing effective diagnostic algorithms requires
experience of the utility of these methods as first- or second-line
studies. As new genes and broader phenotypes in ataxia continue
to be identified, targeted gene panels may overlook recently
identified disease genes. In the case of our cohort, many findings
would not have been made using the panels available at the time
of sequencing. In the case of a negative exome or genome,
systematic re-evaluation at a later time point may reveal a di-
agnosis. Publications of candidate genes potentially causing dis-
eases in humans, as well as internet resources listing rare variants,
aid researchers in finding other families with the same disease.
Most Finnish patients with childhood-onset ataxia are candidates
for exome or genome sequencing when the phenotype and
background do not clearly point to a specific disease entity.
Patients in the cohort had medically actionable findings,
underscoring the importance of exome, or genome sequencing
as a first-line diagnosticmethod. Concurrently, it is crucial for the
clinician to understand the inherent weaknesses of exome se-
quencing, especially the inefficiency concerning current analysis
tools to detect copy number variation and triplet repeats.
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Figure 2 MED23 variant
The P27 heterozygous variant, chr6g.131919485A>G, c.2549T>C, p.(Leu850-
Pro) inMED23 (A) causes the change of a conserved amino acid (B).
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